MeSH term
Frequency | Condition_Probility | Animals | 46 | 0.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Blotting, Western | 15 | 0.0 |
Chromosomes, Human, Pair 2 | 13 | 7.0 |
Chromosomes, Human, Pair 5 | 11 | 9.0 |
*Gene Expression | 2 | 0.0 |
Humans | 183 | 0.0 |
Mice | 31 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 111 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 21 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Translocation, Genetic | 20 | 2.0 |
Tumor Cells, Cultured | 29 | 0.0 |
3T3 Cells | 5 | 0.0 |
*Apoptosis | 5 | 0.0 |
Carrier Proteins/*metabolism | 3 | 0.0 |
Cell Separation | 3 | 0.0 |
Cell Survival | 2 | 0.0 |
Cytokines/*metabolism | 3 | 1.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Immunoblotting | 4 | 0.0 |
Ligands | 3 | 0.0 |
MAP Kinase Signaling System | 3 | 1.0 |
Protein Binding | 4 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 14 | 1.0 |
RNA, Catalytic/metabolism | 3 | 37.0 |
Research Support, U.S. Gov't, P.H.S. | 56 | 0.0 |
Signal Transduction | 13 | 0.0 |
Time Factors | 14 | 0.0 |
Antigens, CD30/metabolism | 3 | 15.0 |
Carrier Proteins/*biosynthesis | 2 | 3.0 |
Comparative Study | 22 | 0.0 |
Hodgkin Disease/metabolism | 3 | 33.0 |
Immunohistochemistry | 46 | 0.0 |
Bone Morphogenetic Proteins/pharmacology | 2 | 6.0 |
Cell Differentiation | 6 | 0.0 |
Cell Line | 12 | 0.0 |
*Proteins | 8 | 1.0 |
*Transforming Growth Factor beta | 4 | 2.0 |
Activin Receptors, Type I/*antagonists & inhibitors | 2 | 66.0 |
Activins/pharmacology | 2 | 20.0 |
Cells, Cultured | 3 | 0.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Drug Interactions | 3 | 0.0 |
Enzyme Activation | 8 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 4 | 0.0 |
Rats | 7 | 0.0 |
Receptors, Transforming Growth Factor beta/*antagonists & inhibitors | 2 | 50.0 |
Trans-Activators/metabolism | 4 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 3 | 0.0 |
Adult | 63 | 0.0 |
Caspases/metabolism | 3 | 0.0 |
Female | 73 | 0.0 |
Male | 88 | 0.0 |
Middle Aged | 57 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 2 | 1.0 |
Prognosis | 22 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 4 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Survival Analysis | 12 | 0.0 |
Treatment Outcome | 9 | 0.0 |
Tumor Markers, Biological/*analysis | 9 | 0.0 |
DNA-Binding Proteins/*metabolism | 5 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
Lymphoma, Large-Cell, Ki-1/*metabolism/pathology | 4 | 66.0 |
Mutation | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 4 | 0.0 |
Phosphorylation | 22 | 0.0 |
*Signal Transduction | 2 | 0.0 |
Trans-Activators/*metabolism | 5 | 0.0 |
Age Factors | 5 | 0.0 |
Gene Expression | 2 | 0.0 |
Immunophenotyping | 16 | 0.0 |
Polymerase Chain Reaction | 14 | 0.0 |
Protein-Tyrosine Kinase/*genetics | 20 | 9.0 |
RNA, Viral/analysis | 3 | 1.0 |
T-Lymphocytes | 2 | 0.0 |
Base Sequence/genetics | 2 | 0.0 |
Child | 49 | 0.0 |
Gene Rearrangement | 4 | 0.0 |
Lymphoma, Large-Cell/*genetics | 2 | 33.0 |
Molecular Sequence Data | 29 | 0.0 |
Protein-Tyrosine Kinase/*genetics/metabolism | 8 | 16.0 |
Translocation, Genetic/*genetics | 3 | 1.0 |
Variation (Genetics) | 2 | 0.0 |
Antigens, Neoplasm/*immunology | 2 | 1.0 |
Mice, Transgenic | 3 | 0.0 |
Protein-Tyrosine Kinase/*immunology | 3 | 20.0 |
Adolescent | 48 | 0.0 |
Aged | 42 | 0.0 |
Child, Preschool | 25 | 0.0 |
Disease Progression | 3 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Retrospective Studies | 10 | 0.0 |
Risk Assessment | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Disease-Free Survival | 5 | 0.0 |
Neoplasm Staging | 6 | 0.0 |
Biopsy, Needle | 3 | 0.0 |
Diagnosis, Differential | 19 | 0.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Tumor Markers, Biological/analysis | 6 | 0.0 |
Apoptosis | 3 | 0.0 |
Cell Division | 8 | 0.0 |
In Situ Hybridization | 7 | 0.0 |
In Situ Nick-End Labeling | 5 | 0.0 |
Kinetics | 5 | 0.0 |
Mice, Nude | 3 | 0.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Apoptosis/drug effects | 2 | 0.0 |
Lymphoma, Large-Cell/*metabolism | 3 | 33.0 |
Gene Expression Regulation, Neoplastic | 11 | 0.0 |
Models, Biological | 5 | 0.0 |
RNA, Neoplasm/biosynthesis | 4 | 2.0 |
Transfection | 11 | 0.0 |
Glycosylation | 2 | 0.0 |
Lymphocyte Activation | 2 | 0.0 |
Phenotype | 4 | 0.0 |
Protein-Tyrosine Kinase/*biosynthesis | 6 | 25.0 |
Aged, 80 and over | 19 | 0.0 |
Protein-Tyrosine Kinase/*analysis/immunology | 4 | 80.0 |
Granuloma, Plasma Cell/*enzymology/pathology | 3 | 100.0 |
Infant | 14 | 0.0 |
Infant, Newborn | 4 | 0.0 |
Soft Tissue Neoplasms/*enzymology/pathology | 2 | 66.0 |
Amino Acid Sequence | 15 | 0.0 |
Lymphoma, Non-Hodgkin/genetics | 2 | 15.0 |
Models, Genetic | 4 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
*Translocation, Genetic | 25 | 2.0 |
Fatal Outcome | 4 | 0.0 |
Killer Cells, Natural/pathology | 2 | 6.0 |
Pregnancy | 3 | 0.0 |
T-Lymphocytes, Cytotoxic/pathology | 2 | 12.0 |
Protein-Tyrosine Kinase/immunology/*metabolism | 2 | 10.0 |
Activin Receptors, Type I/metabolism | 3 | 16.0 |
Granuloma, Plasma Cell/genetics/metabolism/*pathology | 2 | 100.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
Growth Substances/physiology | 2 | 1.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Mice, SCID | 2 | 0.0 |
Protein-Tyrosine Kinase/genetics/*physiology | 3 | 14.0 |
Base Sequence | 25 | 0.0 |
Oncogene Proteins, Fusion/*genetics | 9 | 4.0 |
Translocation, Genetic/genetics | 3 | 3.0 |
Tropomyosin/*genetics | 2 | 11.0 |
Chromosome Mapping | 7 | 0.0 |
Lymphoma, Large-Cell/*genetics/*pathology | 3 | 75.0 |
Protein-Tyrosine Kinase/analysis/*genetics | 3 | 60.0 |
*Chromosomes, Human, Pair 2 | 20 | 6.0 |
In Situ Hybridization, Fluorescence | 20 | 0.0 |
Karyotyping | 8 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics | 3 | 2.0 |
Chromosomes, Human, Pair 2/*genetics | 3 | 1.0 |
Lymphoid Tissue/metabolism | 2 | 7.0 |
Lymphoma, Large-Cell/*genetics/metabolism | 2 | 100.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Neoplasm Proteins/analysis | 3 | 0.0 |
Prospective Studies | 3 | 0.0 |
Protein-Tyrosine Kinase/analysis | 5 | 20.0 |
Survival Rate | 8 | 0.0 |
Chromosome Aberrations | 6 | 1.0 |
DNA Primers/chemistry | 2 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
English Abstract | 5 | 0.0 |
Hodgkin Disease/*genetics | 5 | 27.0 |
Lymphoma, Large-Cell, Ki-1/*genetics | 4 | 66.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Lymphoma, Large-Cell/*genetics/pathology | 3 | 50.0 |
Cell Line, Transformed | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism/*physiology | 2 | 7.0 |
Signal Transduction/*physiology | 7 | 0.0 |
Lymphoma, Large-Cell/*enzymology/genetics/pathology | 2 | 100.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 7 | 5.0 |
Binding Sites | 3 | 0.0 |
Brain/enzymology | 2 | 1.0 |
Cloning, Molecular | 8 | 0.0 |
Gene Library | 2 | 0.0 |
Protein-Tyrosine Kinase/*genetics/*metabolism | 5 | 23.0 |
Transcription, Genetic | 5 | 0.0 |
DNA, Neoplasm/analysis | 6 | 0.0 |
Tumor Markers, Biological/metabolism | 3 | 0.0 |
Serine Endopeptidases/metabolism | 3 | 2.0 |
Antigens, CD30/analysis | 10 | 27.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
*Chromosomes, Human, Pair 5 | 10 | 4.0 |
Gene Fusion | 2 | 2.0 |
Immunoenzyme Techniques | 9 | 0.0 |
DNA Primers | 7 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Flavonoids/pharmacology | 3 | 0.0 |
*MAP Kinase Signaling System | 2 | 1.0 |
Tyrosine/metabolism | 6 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Protein-Tyrosine Kinase/*analysis | 8 | 24.0 |
Lymphoma, Large-Cell, Ki-1/*genetics/immunology/pathology | 2 | 100.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
Protein-Tyrosine Kinase/genetics | 6 | 5.0 |
Activin Receptors | 6 | 33.0 |
Antigens, CD/analysis | 2 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 3 | 0.0 |
Lymphoma, Large-Cell, Ki-1/*diagnosis/enzymology/pathology | 2 | 100.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Tumor Markers, Biological/*metabolism | 4 | 0.0 |
Antibody Specificity | 2 | 0.0 |
COS Cells | 3 | 0.0 |
Combined Modality Therapy | 3 | 0.0 |
Transplantation, Autologous | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
Clathrin/*genetics | 3 | 75.0 |
Inflammation | 3 | 0.0 |
RNA, Messenger/genetics/isolation & purification | 2 | 3.0 |
*Inversion, Chromosome | 3 | 3.0 |
Cell Transformation, Neoplastic | 5 | 0.0 |
Lymphoma, Large-Cell, Ki-1/enzymology/*genetics/pathology | 2 | 100.0 |
Cell Line, Tumor | 7 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Paraffin Embedding | 2 | 0.0 |
Membrane Proteins/*metabolism | 3 | 0.0 |
RNA-Binding Proteins/*metabolism | 3 | 3.0 |
Serine Endopeptidases/*metabolism | 2 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Recurrence | 6 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 2 | 0.0 |
Protein-Tyrosine Kinase/biosynthesis | 2 | 8.0 |
Chromosomes, Human, Pair 2/genetics | 3 | 2.0 |
Chromosomes, Human, Pair 5/genetics | 2 | 2.0 |
Oncogene Proteins, Fusion/genetics/*metabolism | 2 | 5.0 |
Antigens, CD30/*metabolism | 2 | 25.0 |
Lymphoma, Large-Cell, Ki-1/*genetics/pathology | 3 | 75.0 |
Soft Tissue Neoplasms/*metabolism/pathology | 2 | 16.0 |
*Lymphocyte Activation | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Chromosomes, Human, Pair 2/genetics/*ultrastructure | 3 | 75.0 |
Antibodies, Monoclonal/immunology | 5 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Tumor Markers, Biological | 2 | 0.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
Antigens, CD30/*analysis | 3 | 15.0 |
RNA, Neoplasm/analysis | 4 | 1.0 |
Liver Function Tests | 2 | 1.0 |
Lymphatic Metastasis | 2 | 0.0 |
Skin Neoplasms/genetics | 3 | 9.0 |
Nuclear Proteins/biosynthesis/genetics | 2 | 9.0 |
Open Reading Frames | 2 | 0.0 |
Protein-Tyrosine Kinase/*biosynthesis/genetics | 2 | 18.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Adenoviridae/genetics/metabolism | 2 | 6.0 |
Genetic Vectors | 2 | 0.0 |
Transforming Growth Factor beta/metabolism | 2 | 1.0 |
Cattle | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Antigens, CD30/biosynthesis | 2 | 28.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
Apoptosis/physiology | 2 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Lymphoma, Non-Hodgkin/*genetics | 4 | 9.0 |
Nuclear Proteins/*genetics | 5 | 0.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Gene Rearrangement/*genetics | 2 | 5.0 |
Lymphoma, Large-Cell/*genetics/*metabolism | 2 | 100.0 |
Neoplasm Proteins/*analysis/immunology | 2 | 11.0 |
Chromosomes, Human, Pair 2/*ultrastructure | 4 | 44.0 |
Chromosomes, Human, Pair 5/*ultrastructure | 5 | 50.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Sequence Alignment | 2 | 0.0 |
*Gene Rearrangement | 2 | 0.0 |
Activins | 2 | 2.0 |
Inhibins/metabolism | 2 | 13.0 |
Receptors, Transforming Growth Factor beta/*genetics | 2 | 4.0 |
Blotting, Southern | 3 | 0.0 |
Receptors, Growth Factor/metabolism | 2 | 1.0 |
Nuclear Proteins/chemistry/*genetics | 2 | 4.0 |
Activin Receptors, Type I/*biosynthesis | 3 | 100.0 |
*Liver Transplantation | 2 | 1.0 |
Herpesvirus 4, Human/isolation & purification | 2 | 3.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Spectral Karyotyping | 2 | 20.0 |
Proportional Hazards Models | 2 | 0.0 |
Oncogene Proteins, Fusion/genetics/metabolism | 2 | 11.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 2 | 1.0 |
Cell Count | 2 | 0.0 |
